RARE Ultragenyx Pharmaceutical Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1515673 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY20.2%
TTM net income YoY-0.9%
TTM EPS YoY7.3%
Revenue 3-yr CAGR22.8%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-79.5%
Net margin-85.3%
FCF margin-70.1%
EBITDA margin-74.3%
Returns
ROE-656.6%
ROA-37.9%
ROIC (approx.)—
Asset turnover0.44x
Leverage & solvency
Liabilities / assets104.8%
Debt / equity—
Current ratio2.48x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.81x
Accruals ratio-7.2%
Payout ratio—
Capex / revenue0.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $673.00M | $560.00M |
| R&D expense | $750.00M | $698.00M |
| SG&A expense | $349.00M | $321.00M |
| Operating income | -$535.00M | -$536.00M |
| Pretax income | -$571.00M | -$567.00M |
| Income tax | $4.00M | $2.00M |
| Net income | -$575.00M | -$569.00M |
| EBITDA | -$500.00M | -$500.00M |
| EPS (basic) | -5.83 | -6.29 |
| EPS (diluted) | -5.83 | -6.29 |
| Weighted avg. shares (diluted) | 98.60M | 90.50M |
| Balance sheet | ||
| Cash & equivalents | $421.00M | $174.00M |
| Short-term investments | $259.00M | $436.00M |
| Receivables | $158.00M | $122.00M |
| Inventory | $52.00M | $45.00M |
| Current assets | $951.00M | $817.00M |
| PP&E, net | $244.00M | $266.00M |
| Goodwill | $44.00M | $44.00M |
| Intangibles | $176.00M | $178.00M |
| Total assets | $1.53B | $1.50B |
| Current liabilities | $384.00M | $344.00M |
| Total liabilities | $1.60B | $1.24B |
| Shareholders' equity | -$80.00M | $255.00M |
| Shares outstanding | 96.60M | 92.50M |
| Cash flow statement | ||
| Operating cash flow | -$466.00M | -$414.00M |
| Capital expenditure | $6.00M | $7.00M |
| Free cash flow | -$472.00M | -$421.00M |
| Investing cash flow | $236.00M | -$18.00M |
| Financing cash flow | $478.00M | $399.00M |
| Depreciation & amortization | $35.00M | $36.00M |
| Stock-based compensation | $153.00M | $158.00M |
Free plan shows the latest 2 periods; Pro shows all 14 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.